CRISPRjournal Profile Banner
The CRISPR Journal Profile
The CRISPR Journal

@CRISPRjournal

Followers
22K
Following
352
Media
666
Statuses
6K

Cutting-edge peer-reviewed research and analysis on genome editing for the global CRISPR community. EIC @crisprchef | Exec Ed @kevinadavies @liebertpub

New Rochelle, NY
Joined May 2017
Don't wanna be here? Send us removal request.
@KevinADavies
Kevin Davies
29 days
A quick review of the excellent inaugural GATC (Genetic Agency Technology Conference), hosted in Boston by @Dyno_Tx this week. Standout talks by Sonia Vallabh, Allyson Berent @cureangelman and #sicklecell warrior Victoria Gray. cc @ThermalPR @GENbio https://t.co/5CVK5sw2fw
genengnews.com
GATC brought together a broad coalition of researchers and executives in cell and gene therapy, gene editing, drug discovery and AI as well as patients and advocates.
1
2
5
@davidrliu
David R. Liu
29 days
That @US_FDA is recognizing here the urgent need for regulatory strategies to evolve to match the pace of scientific advances in ways that streamline bringing the science safely to patients is incredibly important. I hope these new policies provide a foundation that will
@NEJM
NEJM
30 days
Personalized therapies hold tremendous promise but challenge traditional models of drug and biologic development. The @US_FDA outlines a path to market entry for products where a randomized trial is not feasible. Learn more: https://t.co/kt9YyRP0Hg
8
59
292
@genomcc
Tim McCaffrey, Ph.D.
1 month
I don't want to rain on the CRISPR parade, but this is a very well written article that is cautionary: Reporter’s Notebook: Is Intellia’s Patient Death the Nail in the Coffin for Cas9? https://t.co/vbXuFA0REj via @Inside_PM
Tweet card summary image
insideprecisionmedicine.com
In light of the recent tragedy, many wonder if Intellia's program is the only one affected or if all Cas9-based CRISPR therapies are at risk.
2
3
7
@KevinADavies
Kevin Davies
28 days
New job opportunity... https://t.co/mgXtRkgXMv
0
1
2
@Chevron
Chevron
1 month
Chevron’s AI platform APOLO is transforming shale operations, with up to 20% more accurate production forecasts. Learn how APOLO helps us make smarter, faster decisions.
1
1
21
@BBCBreaking
BBC Breaking News
3 months
Huntington's disease has been successfully treated for the first time, doctors tell BBC
Tweet card summary image
bbc.co.uk
One of the most devastating diseases finally has a treatment that can slow its progression and transform lives, tearful doctors tell BBC.
243
3K
11K
@CRISPRjournal
The CRISPR Journal
3 months
Join our colleagues @GENbio for "The State of Biotech" 4-hr virtual event, today at 11 am ET/8 am PT. Highlights include a keynote interview with George Church with our Exec Editor, @KevinADavies. Registration is free:
@GENbio
Genetic Engineering & Biotechnology News
3 months
🎙️ Don’t miss @daphnezohar, @bradloncar & @cngarabedian of Biotech Hangout at #StateOfBiotech 2025 — Sept 24, 11:10 AM ET. Free summit hosted by @GENbio https://t.co/R79K9887O8 #DrugDiscovery #LifeSciences #StateOfBiotech #BiotechHangout
0
0
4
@zhangf
Feng Zhang
3 months
Deeply saddened by the loss of David Baltimore - a mentor, role model, and scientific giant who shaped so many of us. Most memorably, I was sitting next to David, a month after I started as a baby Assistant Professor, when I learned about CRISPR. His kindness and wisdom will be
Tweet card summary image
nytimes.com
He was only 37 when he made a discovery that challenged the existing tenets of biology and led to an understanding of retroviruses and viruses, including H.I.V.
6
54
581
@CoinDesk
CoinDesk
1 month
⚡️ Consensus Hong Kong 2025 wasn't just a conference. It was a hackathon, a festival, a networking hub, and a deal-making powerhouse all into one. Now that you’ve seen the energy, would you like to join 15,000+ attendees? Get your ticket to be part of the action in 2026. NOW.
19
38
253
@LiebertPub
Mary Ann Liebert Inc
3 months
LAST CHANCE! TODAY, Vicky Smith, PhD, an expert in RNA biology, will provide a practical blueprint for enhancing mRNA quality using proven manufacturing strategies from TriLink’s 25+ years of expertise. REGISTER: https://t.co/iFIVmb6ZKh @TriLinkBioTech
0
1
1
@nevillesanjana
Neville Sanjana
4 months
For those who read our group's lncRNA study published last year, we have recently learned that the Cas13 library included some gRNAs that were not properly filtered for potential off-targets (as described in the Methods). While this does not affect the study's main conclusions,
@nevillesanjana
Neville Sanjana
1 year
🚨🚨🚨 Thrilled to share our newest study — identifying functional long noncoding RNAs using transcriptome-scale RNA-targeting CRISPR screens. 🔎🔎🔎 We hope this scalable approach will be helpful for folks who want to connect noncoding RNAs to phenotypes & diseases.
3
3
38
@KevinADavies
Kevin Davies
3 months
Can You Afford a Cure? The Gene Editing Dilemma - interview with Alta Charo https://t.co/CJrv8WWwIr via @YouTube
1
1
5
@CRISPRjournal
The CRISPR Journal
4 months
The 2025 @ArrigeOrg annual meeting is being held Oct 28-29 in Strasbourg (hybrid). Speakers include: Fabiana Arzuaga, Argentina Marina Cavazzana, France Kazuto Kato, Japan Kiran Musunuru, USA Michael Pepper, SA Pawel Luckow, Poland Julian März, Switzerland https://t.co/ZA5hQ6C6U1
1
0
3
@avapamini
Ava Amini
4 months
When it comes to deep learning for protein engineering, there is strength in simplicity. In a Preview piece @CellCellPress, we highlight work from @CaixiaGaoLab on using fixed-backbone sequence design to engineer genome editors with improved function. 📄 https://t.co/NTjDMY4RP6
1
25
147
@PlntTransformer
Matthew R. Willmann
4 months
Terrana Biosciences is looking to hire two Contract Research Associates to join our Delivery and Transformation team in Durham, NC.
job-boards.greenhouse.io
0
2
2
@yaireinhorn
Yair Einhorn
4 months
Here’s a great interview of @davidrliu - the Co-founder of $BEAM & $PRME, in @GrinsteinJ “Behind the Breakthroughs” podcast in which they talk about CRISPR & Gene Editing & about the way that Prof. Liu’s groundbreaking modalities - Base & Prime Editing, are already saving lives!
@GrinsteinJ
Jonathan D. Grinstein, PhD
4 months
When I first joined @GENbio in 2022, there was one name I kept hearing seemingly weekly: @davidrliu. David Liu's lab invented base and prime editing (gene editing tools now in 20+ clinical trials with early wins against sickle cell, leukemia, and more). In this episode of
10
12
51
@citizens_sanity
Citizens for Sanity
2 days
If your feed makes you feel like sanity is extinct, you’re not alone. Citizens for Sanity is here to confront the radical left head-on, post by post. We take their words and their videos to expose the woke agenda to America. FOLLOW @citizens_sanity today and fight with us.
0
0
8
@CRISPRjournal
The CRISPR Journal
4 months
Our August issue is online now: A special issue on the proceedings of the 2025 Global Observatory for Genome Editing conference, including a post-conference statement from the organizers. https://t.co/sByfaj9u2W (Full access for a limited time.)
1
0
6
@GrinsteinJ
Jonathan D. Grinstein, PhD
4 months
When I first joined @GENbio in 2022, there was one name I kept hearing seemingly weekly: @davidrliu. David Liu's lab invented base and prime editing (gene editing tools now in 20+ clinical trials with early wins against sickle cell, leukemia, and more). In this episode of
1
17
65
@LiebertPub
Mary Ann Liebert Inc
4 months
🚀 The State of Biotech 2025 — hosted by @GENbio. Wed, Sept 24 | 11 AM–3:30 PM ET. Free virtual summit with leaders in AI, CRISPR & biotech innovation. 🔗 https://t.co/OEEmo88D07 #Biotech #LifeSciences #Innovation #StateOfBiotech
1
6
9
@CRISPRjournal
The CRISPR Journal
5 months
"A “Bare Hope of A Result”: The Second CRISPR Patent Appeal" -- Jacob Sherkow @jsherkow https://t.co/eBh6pSDziw
3
5
10
@prageru
PragerU
17 days
Hamas killed 1,200 innocent people on Oct. 7. Yet the world blames Israel. How does that make sense? Larry Elder explains why Israel’s survival is about more than borders—it’s about civilization itself. Watch the Full Video now.
38
88
266